Macarena R Vial1,2, Oisin J O'Connell1, Horiana B Grosu1, Mike Hernandez3, Laila Noor1, Roberto F Casal1,4, John Stewart5, Mona Sarkiss6, Carlos A Jimenez1, David Rice7, Reza Mehran7, David E Ost1, George A Eapen1. 1. Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Department of Pulmonary Medicine, Interventional Pulmonology Unit, Clínica Alemana de Santiago, Universidad del Desarrollo, Santiago, Chile. 3. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Pulmonary and Critical Care Medicine, Michael E. DeBakey Veterans Affairs, Baylor College of Medicine, Houston, TX, USA. 5. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6. Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 7. Department of Thoracic Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract
BACKGROUND AND OBJECTIVE: Standard nodal staging of lung cancer consists of positron emission tomography/computed tomography (PET/CT), followed by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) if PET/CT shows mediastinal lymphadenopathy. Sensitivity of EBUS-TBNA in patients with N0/N1 disease by PET/CT is unclear and largely based on retrospective studies. We assessed the sensitivity of EBUS-TBNA in this setting. METHODS: We enrolled patients with proven or suspected lung cancer staged as N0/N1 by PET/CT and without metastatic disease (M0), who underwent staging EBUS-TBNA. Primary outcome was sensitivity of EBUS-TBNA compared with a composite reference standard of surgical stage or EBUS-TBNA stage if EBUS demonstrated N2/N3 disease. RESULTS: Seventy-five patients were included in the analysis. Mean tumour size was 3.52 cm (±1.63). Fifteen of 75 patients (20%) had N2 disease. EBUS-TBNA identified six while nine were only identified at surgery. Sensitivity of EBUS-TBNA for N2 disease was 40% (95% CI: 16.3-67.7%). CONCLUSION: A significant proportion of patients with N0/N1 disease by PET/CT had N2 disease (20%) and EBUS-TBNA identified a substantial fraction of these patients, thus improving diagnostic accuracy compared with PET/CT alone. Sensitivity of EBUS-TBNA however appears lower compared with historical data from patients with larger volume mediastinal disease. Therefore, strategies to improve EBUS-TBNA accuracy in this population should be further explored.
BACKGROUND AND OBJECTIVE: Standard nodal staging of lung cancer consists of positron emission tomography/computed tomography (PET/CT), followed by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) if PET/CT shows mediastinal lymphadenopathy. Sensitivity of EBUS-TBNA in patients with N0/N1 disease by PET/CT is unclear and largely based on retrospective studies. We assessed the sensitivity of EBUS-TBNA in this setting. METHODS: We enrolled patients with proven or suspected lung cancer staged as N0/N1 by PET/CT and without metastatic disease (M0), who underwent staging EBUS-TBNA. Primary outcome was sensitivity of EBUS-TBNA compared with a composite reference standard of surgical stage or EBUS-TBNA stage if EBUS demonstrated N2/N3 disease. RESULTS: Seventy-five patients were included in the analysis. Mean tumour size was 3.52 cm (±1.63). Fifteen of 75 patients (20%) had N2 disease. EBUS-TBNA identified six while nine were only identified at surgery. Sensitivity of EBUS-TBNA for N2 disease was 40% (95% CI: 16.3-67.7%). CONCLUSION: A significant proportion of patients with N0/N1 disease by PET/CT had N2 disease (20%) and EBUS-TBNA identified a substantial fraction of these patients, thus improving diagnostic accuracy compared with PET/CT alone. Sensitivity of EBUS-TBNA however appears lower compared with historical data from patients with larger volume mediastinal disease. Therefore, strategies to improve EBUS-TBNA accuracy in this population should be further explored.
Authors: Philip Ong; Horiana Grosu; George A Eapen; Macarena Rodriguez; Donald Lazarus; David Ost; Carlos A Jimenez; Rodolfo Morice; Venkata Bandi; Luis Tamara; Lorraine Cornwell; Linda Green; Angela Zhu; Roberto F Casal Journal: Ann Am Thorac Soc Date: 2015-03
Authors: Daniël A Korevaar; Laurence M Crombag; Jérémie F Cohen; René Spijker; Patrick M Bossuyt; Jouke T Annema Journal: Lancet Respir Med Date: 2016-10-20 Impact factor: 30.700
Authors: Roberto F Casal; Donald R Lazarus; Kristine Kuhl; Graciela Nogueras-González; Sarah Perusich; Linda K Green; David E Ost; Mona Sarkiss; Carlos A Jimenez; Georgie A Eapen; Rodolfo C Morice; Lorraine Cornwell; Sheila Austria; Amir Sharafkanneh; Rolando E Rumbaut; Horiana Grosu; Farrah Kheradmand Journal: Am J Respir Crit Care Med Date: 2015-04-01 Impact factor: 21.405
Authors: Christophe Dooms; Kurt G Tournoy; Olga Schuurbiers; Herbert Decaluwe; Frédéric De Ryck; Ad Verhagen; Roel Beelen; Erik van der Heijden; Paul De Leyn Journal: Chest Date: 2015-01 Impact factor: 9.410
Authors: Gerard A Silvestri; Anne V Gonzalez; Michael A Jantz; Mitchell L Margolis; Michael K Gould; Lynn T Tanoue; Loren J Harris; Frank C Detterbeck Journal: Chest Date: 2013-05 Impact factor: 9.410
Authors: Kyung Min Shin; Kyung Soo Lee; Young Mog Shim; Jhingook Kim; Byung Tae Kim; O Jung Kwon; Keunchil Park Journal: Korean J Radiol Date: 2008 Nov-Dec Impact factor: 3.500
Authors: Julian Kirchner; Lino M Sawicki; Felix Nensa; Benedikt M Schaarschmidt; Henning Reis; Marc Ingenwerth; Simon Bogner; Clemens Aigner; Christian Buchbender; Lale Umutlu; Gerald Antoch; Ken Herrmann; Philipp Heusch Journal: Eur J Nucl Med Mol Imaging Date: 2018-08-03 Impact factor: 9.236